Successful electroconvulsive therapy for depression in a man with cerebral amyloid angiopathy

Geert Schurgers1, Baer M G Arts2,3, Alida A Postma3,4

  • 1Department of Psychiatry and Neuropsychology, Maastricht University Medical Centre+, Maastricht, The Netherlands geert.schurgers@mumc.nl.

BMJ Case Reports
|February 6, 2021
PubMed

Insights

Electroconvulsive therapy (ECT) effectively treated severe depression in a 70-year-old man with probable cerebral amyloid angiopathy (CAA). This case highlights potential safety considerations and impacts of ECT on amyloid beta clearance in CAA patients.

Area of Science:

  • Neurology
  • Geriatrics
  • Psychiatry

Background:

  • Cerebral amyloid angiopathy (CAA) involves amyloid beta protein (Aβ) deposition in cerebral blood vessels, increasing hemorrhage risk and cognitive decline.
  • Severe depression is a common comorbidity in elderly patients, impacting quality of life and treatment decisions.

Observation:

  • A 70-year-old male patient presented with probable CAA, diagnosed using modified Boston criteria.
  • The patient also experienced severe depression, necessitating treatment intervention.

Findings:

  • Electroconvulsive therapy (ECT) was administered to treat the patient's severe depression.
  • The depression showed a successful treatment response following ECT.

Implications:

  • This is the first reported case of ECT use in a patient with CAA.
  • Further research is warranted to explore ECT's safety, cognitive effects, and potential influence on Aβ clearance in CAA patients.